ANI Pharmaceuticals' GAAP loss for 9M 2021 was $18.467 million, down 2.4% from $18.913 million in the previous year. Revenue increased 2.6% to $155.207 million from $151.223 million a year earlier.
Warning BlackTerminal uses cookies in order to personalize and improve the usability of the service. If you do not want to use cookies, please change your browser settings. Accept